ClinicalTrials.gg
Status unknownNCT00931593Updated Jul 2, 2009

Transient Lower Esophageal Sphincter Relaxations and High Resolution Manometry

An interventional study of Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization) in Healthy Volunteers, sponsored by Hospices Civils de Lyon. Status unknown at 3 sites in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-07-02.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jul 2009), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Transient lower esophageal sphincter relaxations (tLESr) are the main mechanism of gastro-oesophageal reflux disease. They occur without any deglutition in patients but also in healthy volunteers. They are induced by meal.

The gold standard to detect tLESr is esophageal manometry using perfused Dentsleeve probe.

Esophageal high resolution manometry with solid state sensors was developed in the 90s. The examination is easier and more accurate than perfused manometry. The aim of this study is to validate in healthy volunteers the use of high resolution manometry (Sierra Scientific Instruments, California CA) to detect tLESr.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Transient lower esophageal sphincter relaxation
  • high resolution manometry
  • dentsleeve probe
  • healthy volunteers
03

In context

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,856 studies on the registry; 442 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female between 18 and 60 years
  2. Subject without typical or atypical symptoms of gastro-esophageal reflux disease (heartburn, regurgitation, epigastric pain, chest pain, chronic cough, pharyngeal pain)
  3. Subject without any medication (except oral contraception)
  4. Subject without previous digestive surgery history (except appendicectomy)
  5. Capability to pass manometric probes through each nostril
  6. Subject with health insurance
  7. Written informed consent
  8. No participation to another study at the same time

Exclusion criteria

Exclusion Criteria:

  1. Age under 18 years or upper 60
  2. Pregnant woman or lactation
  3. Incapability to give consent
  4. No written informed consent
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    volunteers

    This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control. The date of perfused manometry is randomized to avoid bias due to examinations' order.

    Device: Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)

Interventions

  • DeviceEsophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)

    Visit V0 (day 0 - 2 to 14 days): * Subject selection * Obtaining of written informed consent Visit V1 (day 0): * Fasting subject * Randomization to determine the examination order * Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial) Visit V2 (day 0 + 1 day): Phone contact Visit V3 (day 0 + 2 to 7 days): * Same as V1 Visit V4 (V3 + 1 day): Phone contact and end of the study

06

What researchers measure

Primary outcomes

  1. The primary outcome is to demonstrate that high resolution manometry allows the detection of meal-induced tLESr. All recordings will be analyzed at the end of each examination and reviewed at the end of the enrolment.

Secondary outcomes

  1. To compare the number of tLESr detected by high resolution manometry and those detected by manometry with perfused dentsleeve probe.

  2. To define the characteristics (duration, relaxation amplitude) of high resolution manometry-detected tLESr.

07

Study locations

1 of 3 sites recruiting
  • Hôpital St André, CHU BORDEAUX
    Bordeaux, 33075, France
    Not yet recruiting
  • Hôpital Edouard Herriot - Hospices Civils de Lyon
    Lyon, 69437, France
    • ROMAN Sabine · Contact · sabine.roman@chu-lyon.fr · 04 72 11 01 36
    • ROMAN Sabine, MD · Principal investigator
    • MION François, MD · Sub investigator
    Recruiting
  • Hôpital Hôtel Dieu, CHU NANTES
    Nantes, 44093, France
    • BRULEY DES VARANNES Stanislas, MD · Contact · 02 40 08 31 65
    • BRULEY DE VARANNES Stanislas, MD · Principal investigator
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2009
First posted
Jul 2, 2009
Start
May 2009
Primary completionEst.
Dec 2009
CompletionEst.
Dec 2009
Last update
Jul 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00931593
First posted
Jul 2, 2009
Start date
May 2009
Primary completion
Dec 2009 (estimated)
Completion
Dec 2009 (estimated)
Last update
Jul 2, 2009

Study contacts

ROMAN Sabine, MD
Contact
sabine.roman@chu-lyon.fr
04 72 11 01 36
ROMAN Sabine, MD
principal investigator · Hospices Civils de Lyon
MION François, MD
principal investigator · Hospices Civils de Lyon
BRULEY DES VARANNES Stanislas, MD
principal investigator · CHRU NANTES
ZERBIB Frank, MD
principal investigator · CHRU BORDEAUX

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion